Nurix Therapeutics (NASDAQ:NRIX) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $26.00 price target on the stock.

Several other equities research analysts have also commented on NRIX. Truist Financial began coverage on shares of Nurix Therapeutics in a research note on Monday, November 24th. They set a “buy” rating and a $30.00 price target on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, October 22nd. Wall Street Zen downgraded shares of Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, October 11th. Piper Sandler lifted their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Morgan Stanley set a $36.00 target price on shares of Nurix Therapeutics and gave the stock an “overweight” rating in a research report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $17.59 on Thursday. The stock has a 50-day simple moving average of $18.50 and a 200-day simple moving average of $13.34. Nurix Therapeutics has a 1 year low of $8.18 and a 1 year high of $22.50. The stock has a market capitalization of $1.35 billion, a PE ratio of -5.79 and a beta of 1.93.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. Nurix Therapeutics had a negative return on equity of 60.99% and a negative net margin of 314.90%.The firm had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Analysts predict that Nurix Therapeutics will post -2.99 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,284 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $472,155.52. The trade was a 14.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds have recently made changes to their positions in the business. Pictet Asset Management Holding SA grew its stake in shares of Nurix Therapeutics by 75.1% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,467,600 shares of the company’s stock valued at $65,780,000 after buying an additional 1,487,060 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Nurix Therapeutics by 73.8% in the third quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock worth $32,109,000 after acquiring an additional 1,475,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after purchasing an additional 1,460,736 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Nurix Therapeutics by 268.7% in the second quarter. Perceptive Advisors LLC now owns 1,096,985 shares of the company’s stock valued at $12,495,000 after buying an additional 799,432 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Nurix Therapeutics by 84.1% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,391,638 shares of the company’s stock valued at $15,851,000 after purchasing an additional 635,668 shares during the last quarter.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Royal Bank of Canada raised its price target to $30 and assigned an “outperform” rating, implying substantial upside vs current levels. Benzinga
• Positive Sentiment: Analyst confirmations: BTIG reaffirmed a “buy” rating with a $30 target, and Needham reaffirmed a “buy” with a $26 target — both signal continued analyst confidence in share appreciation. Benzinga
• Positive Sentiment: Clinical & corporate update: Nurix began dosing first patients in the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL, presented supportive Phase 1 data at ASH 2025 (reported 83% ORR and 22.1‑month PFS), disclosed differentiated preclinical data for IRAK4 degrader GS‑6791 with Gilead, and ended the quarter with ~$592.9M in cash and marketable securities — items that materially improve execution and runway prospects. Corporate Update
• Neutral Sentiment: Quarterly results were mixed: NRIX reported a $0.82 loss per share, slightly better than consensus (-$0.86) and revenue of $13.58M vs. ~$13.41M expected — a modest beat on the headline numbers, but the company remains unprofitable with large negative margins. Press Release
• Negative Sentiment: Conflicting coverage: Zacks ran a headline framing the quarter as a loss that “misses revenue estimates,” which may create investor confusion despite the company-reported slight revenue beat — such mixed messaging can pressure the stock near earnings. Zacks

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.